Reply:

References

1. 1.↵
   2. Hennes EM,
   3. Baumann M,
   4. Schanda K, et al

   . Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 2017;89:900–08 doi:10.1212/WNL.0000000000004312 pmid:28768844

   Abstract/FREE Full Text
2. 2.↵
   2. Hacohen Y,
   3. Wong YY,
   4. Lechner C, et al

   . Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 2018;75:478–87 doi:10.1001/jamaneurol.2017.4601 pmid:29305608

   CrossRefPubMed
3. 3.↵
   2. Dubey D,
   3. Pittock SJ,
   4. Krecke KN, et al

   . Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol 2019;76:301–09 doi:10.1001/jamaneurol.2018.4053 pmid:30575890

   CrossRefPubMed
4. 4.↵
   2. Lopez-Chiriboga AS,
   3. Majed M,
   4. Fryer J, et al

   . Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol 2018;75:1355–63 doi:10.1001/jamaneurol.2018.1814 pmid:30014148

   CrossRefPubMed
5. 5.↵
   2. Salama S,
   3. Khan M,
   4. Levy M, et al

   . Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease. Mult Scler Relat Disord 2019;29:15–22 doi:10.1016/j.msard.2019.01.021 pmid:30658259

   CrossRefPubMed
6. 6.↵
   2. Salama S,
   3. Khan M,
   4. Pardo S, et al

   . MOG antibody-associated encephalomyelitis/encephalitis. Mult Sclr 2019:1352458519837705. [Epub ahead of print] doi:10.1177/1352458519837705 pmid:30907249

   CrossRefPubMed